Protein Kinase CK2 and Epstein-Barr Virus

被引:2
作者
Montenarh, Mathias [1 ]
Graesser, Friedrich A. [2 ]
Goetz, Claudia [1 ]
机构
[1] Saarland Univ, Med Biochem & Mol Biol, Bldg 44 & 47, D-66424 Homburg, Germany
[2] Saarland Univ, Inst Virol, Bldg 44 & 47, D-66424 Homburg, Germany
关键词
protein kinase CK2; phosphorylation; Epstein-Barr virus; EBV-encoded proteins; signaling pathways; p53; review; NF-KAPPA-B; HETEROGENEOUS RIBONUCLEOPROTEIN-K; NASOPHARYNGEAL CARCINOMA-CELLS; LATENT MEMBRANE PROTEIN-1; NUCLEAR ANTIGEN 1; PHOSPHORYLATION SITES; INDUCED APOPTOSIS; CASEIN KINASE-2; BETA-CATENIN; CK2-DEPENDENT MECHANISM;
D O I
10.3390/biomedicines11020358
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein kinase CK2 is a pleiotropic protein kinase, which phosphorylates a number of cellular and viral proteins. Thereby, this kinase is implicated in the regulation of cellular signaling, controlling of cell proliferation, apoptosis, angiogenesis, immune response, migration and invasion. In general, viruses use host signaling mechanisms for the replication of their genome as well as for cell transformation leading to cancer. Therefore, it is not surprising that CK2 also plays a role in controlling viral infection and the generation of cancer cells. Epstein-Barr virus (EBV) lytically infects epithelial cells of the oropharynx and B cells. These latently infected B cells subsequently become resting memory B cells when passing the germinal center. Importantly, EBV is responsible for the generation of tumors such as Burkitt's lymphoma. EBV was one of the first human viruses, which was connected to CK2 in the early nineties of the last century. The present review shows that protein kinase CK2 phosphorylates EBV encoded proteins as well as cellular proteins, which are implicated in the lytic and persistent infection and in EBV-induced neoplastic transformation. EBV-encoded and CK2-phosphorylated proteins together with CK2-phosphorylated cellular signaling proteins have the potential to provide efficient virus replication and cell transformation. Since there are powerful inhibitors known for CK2 kinase activity, CK2 might become an attractive target for the inhibition of EBV replication and cell transformation.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] The Immune Regulatory Role of Protein Kinase CK2 and Its Implications for Treatment of Cancer
    Hong, Huixian
    Benveniste, Etty N.
    BIOMEDICINES, 2021, 9 (12)
  • [42] Biogenesis of Epstein-Barr virus microRNAs
    Kim, Do Nyun
    Lee, Suk Kyeong
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2012, 365 (1-2) : 203 - 210
  • [43] Protein kinase CK2 inhibitors: a patent review
    Cozza, Giorgio
    Pinna, Lorenzo A.
    Moro, Stefano
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2012, 22 (09) : 1081 - 1097
  • [44] Epstein-Barr virus and rheumatoid arthritis
    Balandraud, Nathalie
    Roudier, Jean
    JOINT BONE SPINE, 2018, 85 (02) : 165 - 170
  • [45] Epstein-Barr virus and rheumatoid arthritis
    Bonneville, M
    Scotet, E
    Peyrat, MA
    Saulquin, X
    Houssaint, E
    REVUE DU RHUMATISME, 1998, 65 (06): : 365 - 368
  • [46] Epstein-Barr Virus in Gastric Carcinoma
    Nishikawa, Jun
    Yoshiyama, Hironori
    Iizasa, Hisashi
    Kanehiro, Yuichi
    Nakamura, Munetaka
    Nishimura, Junichi
    Saito, Mari
    Okamoto, Takeshi
    Sakai, Kouhei
    Suehiro, Yutaka
    Yamasaki, Takahiro
    Oga, Atsunori
    Yanai, Hideo
    Sakaida, Isao
    CANCERS, 2014, 6 (04): : 2259 - 2274
  • [47] Epstein-Barr virus and multiple sclerosis
    Pohl, Daniela
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 286 (1-2) : 62 - 64
  • [48] Epstein-Barr virus and gastric carcinoma
    Fukayama, Masashi
    PATHOLOGY INTERNATIONAL, 2010, 60 (05) : 337 - 350
  • [49] Emergence of protein kinase CK2 as a key target in cancer therapy
    Trembley, Janeen H.
    Chen, Zhong
    Unger, Gretchen
    Slaton, Joel
    Kren, Betsy T.
    Van Waes, Carter
    Ahmed, Khalil
    BIOFACTORS, 2010, 36 (03) : 187 - 195
  • [50] Epstein-Barr Virus History and Pathogenesis
    Yu, Hui
    Robertson, Erle S.
    VIRUSES-BASEL, 2023, 15 (03):